Myopharm strives to enhance & prolong lives in those with metabolic and inflammatory diseases

Myopharm Limited is a clinical-stage Australian-based biopharmaceutical company, developing targeted therapies for multiple chronic diseases.

In our portfolio we have pharmaceutical drug candidates & clinically validated consumer health products.

We were incredibly honoured that the American Diabetes Association(ADA) featured Myopharm Limited in the Thought Leadership Film Series, a part of ADA’s 84th Scientific Sessions program in June 2024.

See our latest OMNI-D® Television Commercial

PORTFOLIO


Drug Candidates

Myopharm’s lead drug candidate TriGlytza®, reduces progressive pancreatic Beta cell loss through targeted action on multiple pro-inflammatory mediators within the PGE2 & RAS signalling pathways.

Consumer Health

Myopharm's clinically validated food for special medical purpose products are high quality products for diabetes & chronic disease.

OUR MISSION


Myopharm strives to enhance & prolong lives through the development of specialised assets that effectively treat multiple metabolic mediated inflammatory chronic diseases.

Our goal is to empower patients, healthcare providers & communities globally through our innovative suite of products that treat and manage chronic diseases.


INVESTOR CENTRE